Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Xenon Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Xenon Pharmaceuticals Inc.’s stock price such as:

• Xenon Pharmaceuticals Inc.’s current stock price and volume
• Why Xenon Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for XENE from analysts
• XENE’s stock price momentum as measured by its relative strength

About Xenon Pharmaceuticals Inc. (XENE)

Before we jump into Xenon Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Want to learn more about Xenon Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Xenon Pharmaceuticals Inc..

Xenon Pharmaceuticals Inc.’s Stock Price as of Market Close

As of September 25, 2026, 1:16 PM, CST, Xenon Pharmaceuticals Inc.’s stock price was $36.840.

Xenon Pharmaceuticals Inc. is down 3.21% from its previous closing price of $38.060.

During the last market session, Xenon Pharmaceuticals Inc.’s stock traded between $36.820 and $38.260. Currently, there are approximately 99.61 million shares outstanding for Xenon Pharmaceuticals Inc..

Xenon Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Xenon Pharmaceuticals Inc. Stock Price History

Xenon Pharmaceuticals Inc.’s (XENE) price is currently down 38.82% so far this month.

During the month of September, Xenon Pharmaceuticals Inc.’s stock price has reached a high of $61.750 and a low of $36.070.

Over the last year, Xenon Pharmaceuticals Inc. has hit prices as high as $72.660 and as low as $35.970. Year to date, Xenon Pharmaceuticals Inc.’s stock is down 17.8%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Xenon Pharmaceuticals Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 24, 2026, there was 1 analyst who downgraded Xenon Pharmaceuticals Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Xenon Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Xenon Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Xenon Pharmaceuticals Inc. (XENE) by visiting AAII Stock Evaluator.

Relative Price Strength of Xenon Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 24, 2026, Xenon Pharmaceuticals Inc. has a weighted four-quarter relative price strength of -6.77%, which translates to a Momentum Score of 37 and is considered to be Weak.

Want to learn more about how Xenon Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Xenon Pharmaceuticals Inc. Stock Price: Bottom Line

As of September 25, 2026, Xenon Pharmaceuticals Inc.’s stock price is $36.840, which is down 3.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Xenon Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.